Pharmacological treatments for personality disorders

International Review of Psychiatry

Volumn 23, Issue 3, 2011, Pages 303-309

  Paris, Joel ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; PERSONALITY DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOTHERAPY; REMISSION; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; HUMANS; PERSONALITY DISORDERS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 80053036236     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2011.586993     Document Type: Article

References (66)

1. Arndt, I.O.; Dorozynski, L.; McLellan, A.T.; Woody, G.E.; & O'Brien, C.P. (1992). Controlled study of desipramine treatment of cocaine dependence in methadone treated patients. Archives of General Psychiatry, 49, 888-893.
2. Arndt, I.O.; McClellan, A.T.; Dorozynsky, L.; Woody, G.E.; & O'Brien, C.P. (1992). Desipramine treatment for cocaine dependence: Role of antisocial personality disorder. Journal of Nervous and Mental Disease, 182, 151-156. (Pubitemid 24137667)
3. Baker-Glenn, E.; Steels, M.; & Evans, C. (2010). Use of psychotropic medication among psychiatric out-patients with personality disorder. Psychiatrist, 34, 83-86.
4. Battaglia, J.; Wolff, T.K.; Wagner-Johnson, D.S.; Rush, A.J.; Carmody, T.J.; & Basco, M.R. (1999). Structured diagnostic assessment and depot fl uphenazine treatment of multiple suicide attempters in the emergency department. International Clinical Psychopharmacology, 14, 361-372. (Pubitemid 29531386)
5. Binks, C.A.; Fenton, M.; McCarthy, L.; Lee, T.; Adams, C.E.; & Duggan, C. (2006). Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews (1):CD005653.
6. Bogenschutz, M.P.; & Nurnberg, G.H. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 104-109.
7. Coccaro, E.F.; & Kavoussi, R.J. (1997). Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General Psychiatry, 54, 1081-1088. (Pubitemid 27524373)
8. Cowdry, R.W.; & Gardner, D.L. (1988). Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifl uoperazine, and tranylcypromine. Archives of General Psychiatry, 45, 111-119. (Pubitemid 18052841)
9. De la Fuente, J.M.; & Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology, 4, 479-486.
10. Duggan, C.; Huband, N.; Smailagic, N.; Ferriter, M.; & Adams, C. (2009). The use of pharmacological treatments for people with personality disorder: A systematic review of randomized controlled trials. Personality and Mental Health, 2, 119-170.
11. Evidence-Based Medicine Working Group (1992). Evidencebased medicine: A new approach to teaching the practice of medicine. Journal of the American Medical Association, 268, 2420-2425.
12. Frankenburg, F.R.; & Zanarini, M.C. (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry, 63, 442-446. (Pubitemid 34507223)
13. Herpertz, S.C.; Zanarini, M.C.; Schulz, C.S.; Siever, L.; Lieb, K.; Moller, H.J.; & Task Force on Personality Disorders, WFSBP (2007). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of personality disorders. World Journal of Biological Psychiatry, 8, 212-244. (Pubitemid 350018476)
14. Hollander, E.; Swann, A.C.; Coccaro, E.F.; Jiang, P.; & Smith, T.B. (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. American Journal of Psychiatry, 162, 621-624. (Pubitemid 40343936)
15. Hollander, E.; Tracy, K.A.; Swann, A.C.; Coccaro, E.F.; McElroy, S.L.; Wozniak, P.; Nemeroff, C.B. (2003). Divalproex in the treatment of impulsive aggression: Efficacy in cluster B personality disorders. Neuropsychopharmacology, 28, 1186-1197.
16. Ingenhoven, T.; Lafay, P.; Rinne, T.; Passchier, J.; & Duivenvoorden, H. (2010). Effectiveness of pharmacotherapy for severe personality disorders; meta-analyses of randomized controlled trials. Journal of Clinical Psychiatry, 71, 14-25.
17. Ioannidis, J.P.A. (2005). Why most published research findings are false. PLoS Medicine, 2, e124.
18. Kavoussi, R.J.; & Coccaro, E.F. (1998). Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. Journal of Clinical Psychiatry, 59, 676-680. (Pubitemid 29068313)
19. Kendall, T.; Pilling, S.; Tyrer, P.; Duggan, C.; Burbeck, R.; Meader, N.; & Taylor, C. (2009). Borderline and antisocial personality disorders: Summary of NICE guidance. National Institute of Clinical Excellence. Available online: http://www.nice.org.uk/
20. Kirsch, I.; Deacon, B.J.; Huedo-Medina, T.B.; Scoboria, A.; Moore, T.J.; & Johnson, B.T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5, e45.
21. Koenigsberg, H.W.; Harvey, P.D.; Mitropoulou, V.; Schmeidler, J.; New, A.S.; Goodman, M.; Siever, L.J. (2002). Characterizing affective instability in borderline personality disorder. American Journal of Psychiatry, 159, 784-788. (Pubitemid 34465052)
22. Lieb, K.; Vollm, B.; Rucker, G.; Timmer, A.; & Stoffers, J.M. (2010). Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. British Journal of Psychiatry, 196, 4-12.
23. Leal, J.; Ziedonis, D.; & Kosten, T. (1994). Antisocial personality disorder as a prognostic factor for pharmacotherapy of cociane depnedience. Drug and Alcohol Dependence, 35, 31-35. (Pubitemid 24135901)
24. Leone, N.F. (1982). Response of borderline patients to loxapine and chlorpromazine. Journal of Clinical Psychiatry, 43, 148-150. (Pubitemid 12156641)
25. Linehan, M.M. (1993). Dialectical Behavior Therapy for Borderline Personality Disorder. New York: Guilford.
26. Links, P.S.; Steiner, M.; Boiago, I.; & Irwin, D. (1990). Lithium therapy for borderline patients: Preliminary findings. Journal of Personality Disorders, 4, 173-181. (Pubitemid 20339898)
27. Markowitz, P.J.; Calabrese, J.R.; Schulz, S.C.; & Melzer, H.Y. (1991). Fluoxetine in the treatment of borderline and schizotypal personality disorders. American Journal of Psychiatry, 148, 1064-1067.
28. Markowitz, P.J.; & Wagner, S.L. (1995). Venlafaxine in the treatment of borderline personality disorder. Psychopharmacology Bulletin, 31, 773-777.
29. Mercer, D.; Douglass, A.B.; & Links, P.S. (2009). Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. Journal of Personality Disorders, 23, 156-174.
30. Newcomer, J.W.; & Haupt, D.W. (2006). The metabolic effects of antispsychotic medication. Canadian Journal of Psychiatry, 51, 480-491.
31. Newton-Jones, G.; Tyrer, P.; & Johnson, T. (2006). Personality disorder and the outcome of depression: Meta-analysis of published studies. British Journal of Psychiatry, 188, 13-20. (Pubitemid 43021921)
32. Nickel, M.K.; Nickel, C.; Mitterlehner, F.O.; Tritt, K.; Lahmann, C.; Leiberich, P.K.; Loew, T.H. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 65, 1515-1519.
33. Nickel, M.K.; Muechlbacher, M.; Nickel, C.; Kettler, C.; Gil, F.P.; Fartacek, R. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. American Journal of Psychiatry, 163, 833-838. (Pubitemid 44464531)
34. Nose, M. (2009). No signifi cant difference between olanzapine and placebo for improvement in borderline personality disorder symptoms. Evidence Based Mental Health, 12, 89, doi:10.1136/ebmh.12.3.89.
35. Nose, M.; Cipriani, A.; & Biancosino, B. (2009). Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. International Clinical Psychopharmacology, 21, 345-353. (Pubitemid 44498276)
36. Oldham, J.M.; Gabbard, G.O.; Goin, M.K.; Gunderson, J.; Soloff, P.; Spiegel, D.; Phillips, K.A. (2001). Practice guideline for the treatment of borderline personality disorder. American Journal of Psychiatry, 158, S1-52.
37. Paris, J. (2008). Prescriptions for the Mind. New York: Oxford University Press.
38. Paris, J. (2010a). Effectiveness of differing psychotherapy approaches in the treatment of borderline personality disorder. Current Psychiatry Reports, 12, 56-60.
39. Paris, J. (2010b). The Use and Misuse of Psychiatric Drugs. London: Wiley.
40. Paris, J.; Gunderson, J.G.; & Weinberg, I. (2007). The interface between borderline personality disorder and bipolar spectrum disorder. Comprehensive Psychiatry, 48, 145-154. (Pubitemid 46204668)
41. Parsons, B.; Quitkin, F.M.; McGrath, P.J.; Stewart, J.W.; Tricamo, E.; Ocepek-Welikson, K.; Nunes, E. (1989). Phenelzine, imipramine and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacology Bulletin, 25, 524-534. (Pubitemid 20137977)
42. Philipsen, A.; Schmahl, C.; & Lieb, K. (2004a). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37, 196-199. (Pubitemid 39286920)
43. Philipsen, A.; Richter, H.; Schmahl, C.; Peters, J.; Rusch, N.; Bohus, M.; & Lieb, K. (2004b). Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Journal of Clinical Psychiatry, 65, 1414-1419.
44. Rinne, T.; van den Brink, W.; Wouters, L.; & van Dyck, R. (2002). SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048-2054. (Pubitemid 35423864)
45. Salzman, C.; Wolfson, A.N.; Schatzberg, A.; Looper, J.; Henke, R.; Albanese, M.; Miyawaki, E. (1995). Effect of fl uoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23-29.
46. Schulz, S.S.; Zanarini, M.C.; Bateman, A.; Bohus, M.; Detke, H.D.; Trzaskoma, Q.; Corya, S. (2008). Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. British Journal of Psychiatry, 193, 485-492.
47. Serban, G.; & Siegel, S. (1984). Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. American Journal of Psychiatry, 141, 1455-1458. (Pubitemid 14023951)
48. Shorter, E. (2009). Before Prozac. New York: Oxford University Press.
49. Siever, L.J.; & Davis, K.L. (1991). A psychobiological perspective on the personality disorders. American Journal of Psychiatry, 148, 1647-1658.
50. Simpson, E.B.; Yen, S.; Costello, E.; Rosen, K.; Begin, A.; Pistorello, J.; & Pearlstein, T. (2004). Combined dialectical behavior therapy and fl uoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 379-385.
51. Soler, J.; Pascual, J.C.; Campins, J.; Barrachina, J.; Puigdemont, D.; Alvarez, E.; & Pérez, V. (2005). Double-blind, placebocontrolled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry, 162, 1221-1224. (Pubitemid 40770712)
52. Soloff, P.H.; Cornelius, J.; George, A.; Nathan, S.; Perel, J.M.; & Ulrich, R.F. (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry, 50, 377-385. (Pubitemid 23143127)
53. Soloff, P.; George, A.; Nathan, R.S.; Schulz, P.M.; Ulrich, R.F.; & Perel, J.M. (1986a). Progress in pharmacotherapy of borderline disorders: A double-blind study of amitryptyline, haloperidol, and placebo. Archives of General Psychiatry, 43, 691-697. (Pubitemid 16094181)
54. Soloff, P.H.; George, A.; Nathan, S.; Schulz, P.M.; Ulrich, R.F.; & Perel, J.M. (1986b). Amitriptyline and haloperidol in unstable and schizotypal borderline disorders. Psychopharmacology Bulletin, 22, 177-182. (Pubitemid 16101352)
55. Soloff, P.H.; George, A.; Nathan, S.; Schulz, P.M.; Cornelius, J.R.; Herring, J.; & Perel, J.M. (1989). Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. Journal of Clinical Psychopharmacology, 9, 238-246. (Pubitemid 19198957)
56. Stoffers, J.; Völlm, B.A.; Rücker, G.; Timmer, A.; Huband, N.; & Lieb, K. (2010). Pharmacological interventions for borderline personality disorder. Cochrane Database of Systematic Reviews, Issue 6. Art. No.: CD005653. DOI: 10.1002/14651858.CD005653.pub2
57. Tritt, K.; Nickel, C.; Lahmann, C.; Leiberich, P.K.; Rother, W.K.; Loew, T.H.; & Nickel, M.K. (2005). Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology, 19, 287-291. (Pubitemid 40694947)
58. Tyrer, P.; & Bateman, A.W. (2004). Drug treatment for personality disorders. Advances in Psychiatric Treatment, 10, 389-398. (Pubitemid 39232445)
59. Verkes, R.J.; Van der Mast, R.C.; Hengeveld, M.W.; Tuyl, J.P.; Zwinderman, A.H.; & Van Kempen, G.M. (1998). Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. American Journal of Psychiatry, 155, 543-547. (Pubitemid 28207452)
60. Wilcox, J.A. (1995). Divalproex sodium as a treatment for borderline personality disorder. Annals of Clinical Psychiatry, 7, 33-37.
61. Zanarini, M.C.; & Frankenburg, F.R. (2001). Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849-854. (Pubitemid 33131170)
62. Zanarini, M.C.; Frankenburg, F.R.; Khera, G.S.; & Bleichmar, J. (2001). Treatment histories of borderline inpatients. Comprehensive Psychiatry, 42, 144-150. (Pubitemid 32207250)
63. Zanarini, M.C.; & Frankenburg, F.R. (2003). Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry, 160, 167-169. (Pubitemid 36042442)
64. Zanarini, M.C.; Frankenburg, F.R.; Dubo, E.D.; Sickel, A.E.; Trikha, A.; & Levin, A. (1998). Axis I comorbidity of borderline personality disorder. American Journal of Psychiatry, 155, 1733-1739. (Pubitemid 28547499)
65. Zanarini, M.C.; Frankenburg, F.R.; & Parachini, E.A. (2004). A preliminary, randomized trial of fl uoxetine, olanzapine, and the olanzapine-fl uoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65, 903-907.
66. Ziegenhorn, A.A.; Roepke, S.; Schommer, N.C.; Merkl, A.; Danker-Hopfe, H.; Perschel, F.H.; Lammers, C.H. (2009). Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 29, 170-173.